Related Experiment Video
Updated: Aug 13, 2026

Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids
Published on: June 2, 2023
Epithelial CXCL1 tracks clinical remission in inflammatory bowel disease in a disease-specific manner
Sanmi E Alake1, Anil H Kadam2,3, Traci Jester1
1Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Alabama at Birmingham, Birmingham, AL, United States.
Introduction:
Stem cell-derived organoids are promising platforms for therapeutic screening in inflammatory bowel disease (IBD), but identifying functional organoid readouts with translational utility is challenging. Colon epithelial organoids from patients with ulcerative colitis (UC) overexpress chemokines CXCL1, CXCL11, CCL2, and CCL28, yet whether these epithelial inflammatory signatures correlate with disease activity and treatment response is unclear. This brief report explores whether organoid-retained chemokines correlate with disease activity and therapeutic outcomes.
Methods:
We interrogated three bulk and two single-cell transcriptomic datasets from IBD clinical trials encompassing anti-TNFα and anti-integrin therapies to determine whether epithelial chemokines retained in UC organoids are associated with clinical response and distinguish treatment responders from non-responders to biologic therapy across multiple IBD patient cohorts.
Results:
In bulk transcriptomic data, CXCL1, CXCL11, and CCL2 were elevated in active UC and normalized only in patients achieving clinical remission, independent of therapy class, with persistent chemokine overexpression in non-responders. Linear regression analysis demonstrated that CXCL1 showed the strongest and most consistent association with Mayo clinical disease activity scores across independent cohorts. Single-cell analysis of epithelial cell types identified CXCL1 as the only chemokine significantly enriched in both enterocytes and LGR5-positive stem cells in UC. CXCL1 expression normalized in remission but remained elevated in non-remission patients, and this pattern was recapitulated in LGR5-high stem cell states. Epithelial CXCL1 expression was not associated with clinical remission in Crohn's disease.
Conclusions:
CXCL1 is a remission-associated epithelial chemokine in UC and may represent a candidate biomarker and functional endpoint for epithelial-directed therapeutic screening using patient-derived organoid models.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
